Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Next Previous
Trial Profile

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Glioma; Hepatoblastoma; Langerhans cell histiocytosis; Lymphoma; Malignant melanoma; Medulloblastoma; Neuroblastoma; Neuroectodermal tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Phaeochromocytoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Wilms' tumour
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms Pediatric MATCH

Most Recent Events

  • 03 Jun 2025 Planned End Date changed from 16 Apr 2025 to 30 Sep 2027.
  • 17 Apr 2024 Planned End Date changed from 30 Sep 2027 to 16 Apr 2025.
  • 02 Jan 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top